secwatch.observer — SEC 8-K summary
======================================

Issuer:     TFF Pharmaceuticals, Inc. (—)
CIK:        0001733413
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001213900-24-098457
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 1.02, 2.05, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TFF Pharmaceuticals dissolves, terminates all employees, appoints new CEO to wind down
--------------------------------------------------------------------------------

- Board approved Plan of Dissolution subject to stockholder vote; license pact with UT Austin terminated.
- Substantially all employees terminated Nov 15; estimated $1.8M in severance and exit costs.
- Entire board and top officers (CEO, CFO, CMO) resigned; Craig Jalbert appointed sole director/officer.
- Jalbert to receive $10K/month until shareholder vote, then $50K/year for three years post-dissolution.
- Company will wind down operations and dissolve, pending stockholder approval of the plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733413/000121390024098457/0001213900-24-098457-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733413/000121390024098457/ea0221102-8k_tffpharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-098457

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer